Notizie AIOM – anno XV
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore al seno è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...Leggi tutto
EC Approves Frontline Pembrolizumab for PD-L1+ Metastatic NSCLC
January 31st, 2017 - The European Commission has expanded the indication for pembrolizumab to include the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) that expresses PD-L1 on ≥50% of cells and does not harbor an EGFR or ALK ...Leggi tutto
IASLC Statement on Philip Morris’ New Manifesto Highlights the Importance of Tobacco Control
February 2nd, 2017 - On February 1, 2017, the International Association for the Study of Lung Cancer (IASLC) issued the following statement: “According to its own public reports, in 2016 Phillip Morris manufactured 800 billion cigarettes. Thus, views with some skepticism ...Leggi tutto
FDA Grants Pembrolizumab Priority Review in Second-Line Bladder Cancer
February 3rd, 2017 - The FDA has granted a priority review to a supplemental Biologics License Application (sBLA) for pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who progress following platinum-containing chemotherapy, ...Leggi tutto
FDA Grants Priority Review to Frontline Pembrolizumab for Urothelial Carcinoma
February 3rd, 2017 - The FDA has granted a priority review to pembrolizumab as a treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, according to Merck, the developer of the PD-1 inhibitor. The priority review was based on ...Leggi tutto
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
The European Society for Medical Oncology (ESMO) is one of the leading societies of oncology professionals in the world. Approximately 30% of the 13 000 ESMO members are below the age of 40 and thus meet the society's definition of young oncologists (YOs). ESMO has identified ...Leggi tutto